Why Is PULSE BIOSCIENCES IN (PLSE) Stock Up Today?

Why PLSE stock is up today

PLSE stock surged 11.77% to $54.53 in a volatile session driven by a new buy rating from Freedom Capital and strong intraday momentum. The stock opened with a modest 0.8% gap up and climbed to a high of $58.90 before settling at $54.44. The move reflects renewed investor interest in the biotech firm following the initiation of coverage with a positive outlook.

What Happened

Freedom Capital Markets initiated coverage on Pulse Biosciences with a Buy rating and a $73 price target. This development came as the stock was already showing strength in the intraday session. The stock’s early buyers pushed it well above the prior close and into a new 52-week high. The COO, Liane Rae Teplitsky, has also been active in the market, buying shares on two separate occasions in late August and early September. These transactions suggest internal confidence in the company’s direction. The broader healthcare sector also saw movement, with Pulse Biosciences highlighted among stocks making significant intraday gains.

What The Data Shows

PLSE opened at $49.20 and reached a high of $58.90, with volume already at 0.8M shares, 2.0 times the 3-month average. The stock closed the session at $54.44, near the top of its range. The stock has a market cap of $3.8B and is currently unprofitable, with an EPS TTM of -1.18. Its beta of 1.62 indicates higher volatility than the market. The stock’s 52-week range is $12.56 to $55.37, and it printed one fresh 52-week low and 30 fresh 52-week highs on September 9.

What To Watch

The stock is currently in a period of heightened coverage, with three stories published in the last 36 hours. Investors should monitor the breadth of coverage and any follow-up analyst activity for further signals.